AstraZeneca’s Tozorakimab Shows Promise in COPD Phase III Trials

AstraZeneca’s experimental biologic tozorakimab has delivered strong results in two Phase III studies for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbation rates when added to standard inhaled therapies.

The OBERON and TITANIA trials demonstrated consistent benefits across diverse patient groups, including both current and former smokers, regardless of eosinophil levels or lung function. The treatment was also generally well tolerated, with a favourable safety profile reported.

Tozorakimab works by blocking interleukin-33 (IL-33), a key driver of inflammation and mucus production in COPD. Its broad mechanism may allow it to benefit a wider patient population compared to some existing biologics.

As the COPD treatment landscape evolves with new add-on therapies, tozorakimab could emerge as a significant option if approved, with further studies underway to confirm its long-term potential and clinical value.

27-03-2026